Ann: HSV-2 Phase IIa Results Investor Webinar, page-130

Thanks Lex, I actually just wrote my thoughts in the thread. But I agree. I'm balls deep but almost in the green again on AHZ, so if growth continues the next two days I'll be in a good position to take advantage of whatever happens. You're right though, I want to see decisive action on the Immunotherapies division, including getting rid of it if the Vax is a dud. I don't want to see another 5 years of funding through CR for a HPV vaccine. Palm it off to someone else if it is a dud (it might not be).

This would be very beneficial to AHZs bottom line over the next 6 months.

If it's not a dud and there's a deal in the offing, well then we have nothing to worry about.